Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health
You may also be interested in...
China Releases County-level Public Hospital Reform Guidelines
The reforms will slash drug markups and promote the Essential Drug List and traditional Chinese medicine to control medical expenditures.
Asia Spotlight: With Change On The Horizon, Current Business Models In China Are Not Sustainable – So What’s Next?
Health care reforms will turn the China health care market upside now, meaning that pharma companies must prepare for a new sustainable business model.
Bayer Taps Deeper Into Beijing’s Biotech Potential, Renews Partnership With Tsinghua
Latest research deal for Bayer underscores Beijing’s growing importance as a biotech hub.